维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09887 维立志博-B

交易中 09-04 15:49:29

63.700

-4.000

-5.91%

最高69.000	最低63.600	成交量367.05万
今开69.000	昨收67.700	日振幅7.98%
总市值126.76亿	流通市值126.13亿	总股本1.99亿
成交额2.39亿	换手率1.85%	流通股本1.98亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"维立志博-B","latestPrice":63.7,"timestamp":1788508160767,"preClose":67.7,"halted":0,"volume":3670500,"delay":0,"changeRate":-0.059084194977843424,"floatShares":198000000,"shares":199000000,"eps":-1.4138281207122303,"marketStatus":"交易中","change":-4,"latestTime":"09-04 15:49:29","open":69,"high":69,"low":63.6,"amount":238820787,"amplitude":0.079764,"askPrice":63.75,"askSize":4300,"bidPrice":63.7,"bidSize":1900,"shortable":3,"etf":0,"ttmEps":-1.6090205299859655,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1788509400000},"marketStatusCode":2,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":67.7,"openAndCloseTimeList":[[1788485400000,1788494400000],[1788498000000,1788508800000]],"volumeRatio":1.903913,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09887","defaultTab":"news","newsList":[{"id":"1175698768","title":"异动解读｜维立志博-B盘中下跌5.32%，股东大额减持叠加中期亏损扩大持续承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1175698768","media":"行情直击","labels":["shareholding"],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175698768?lang=zh_cn&edition=full","pubTime":"2026-09-04 14:05","pubTimestamp":1788501948,"startTime":"0","endTime":"0","summary":"9月4日，维立志博-B盘中下跌5.32%，报64.1港元，成交额1.95亿港元。此外，公司此前披露中期业绩，上半年净亏损约2.22亿元，同比扩大33.38%，研发成本同比增长44.92%至1.91亿元，尚无产品销售收入，亏损持续扩大对市场情绪形成压制。维立志博-B是一家专注于抗体新药研发及商业化的生物科技公司，核心产品LBL-024的NDA已获国家药监局受理，多项临床管线正在推进中。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"维立志博-B承压下跌，股东大额减持叠加亏损扩大","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664538881","title":"维立志博-B(09887)存仓市值总计6.69亿港元 股东将971.37万股股票存入摩根士丹利香港证券","url":"https://stock-news.laohu8.com/highlight/detail?id=2664538881","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664538881?lang=zh_cn&edition=full","pubTime":"2026-09-04 08:34","pubTimestamp":1788482087,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，9月3日，维立志博-B(09887)出现仓位异动，存仓市值总计6.69亿港元，占比5.05%。该公司股东将971.37万股股票存入摩根士丹利香港证券，持股比例增加4.92%。此前维立志博-B公布2026年中期业绩，实现收入3596.9万元，研发成本约1.91亿元，同比增长44.92%;行政开支同比增加15.5%至4140万元，期内亏损约2.22亿元，同比增长33.38%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491868.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252152.HKD","HK0000252160.HKD","09887","HK0000500386.USD","BK1161","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664879114","title":"上海汉康私募基金管理有限公司减持维立志博-B(09887.HK)284.6万股 每股作价约65.35港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664879114","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664879114?lang=zh_cn&edition=full","pubTime":"2026-09-03 19:16","pubTimestamp":1788434207,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09887","HK0000252152.HKD","HK0000500386.USD","HK0000252160.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117162441","title":"维立志博-B：苑全红减持，好仓比例降至4.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=1117162441","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117162441?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:24","pubTimestamp":1788427448,"startTime":"0","endTime":"0","summary":"苑全红于2026年9月2日以每股均价65.3481港元卖出维立志博-B（09887）股份284.60万股，涉资约1.86亿港元。苑全红此次减持前持有维立志博-B好仓1257.28万股，占比6.36%；减持后持股量为972.68万股，好仓比例降至4.92%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159316088","title":"维立志博-B：上海汉康私募基金管理有限公司减持，好仓比例降至4.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=1159316088","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159316088?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:16","pubTimestamp":1788427006,"startTime":"0","endTime":"0","summary":"上海汉康私募基金管理有限公司于2026年9月2日以每股均价65.3481港元卖出维立志博-B股份284.60万股，涉资约1.86亿港元。上海汉康私募基金管理有限公司此次减持前持有维立志博-B好仓1257.28万股，占比6.36%；减持后持股量为972.68万股，好仓比例降至4.92%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664267298","title":"【券商聚焦】招银国际维持维立志博（09887）“买入”评级 聚焦LBL-024于WCLC/ESMO的数据读出","url":"https://stock-news.laohu8.com/highlight/detail?id=2664267298","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664267298?lang=zh_cn&edition=full","pubTime":"2026-09-03 13:12","pubTimestamp":1788412331,"startTime":"0","endTime":"0","summary":"该机构期待其在WCLC及ESMO上的多项数据读出。该机构认为，LBL-024有望发展为适用范围广泛的下一代IO基石产品。一线BTC方面，公司亦在规划III期研究，预计于2027年上半年提交IND，并于10月ESMO公布Ph1b数据。该机构认为，WCLC及ESMO即将公布的数据将成为公司估值重估的重要催化剂。","market":"us","thumbnail":"https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990546","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664897742","title":"里昂：维立志博-B目标价升至116.9港元 维持“跑赢大市”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2664897742","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664897742?lang=zh_cn&edition=full","pubTime":"2026-09-02 17:01","pubTimestamp":1788339660,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端里昂发布研报称，维立志博-B（09887）上半年合作收入为3，600万元人民币，该行预期催化剂包括LBL-024用于一线非小细胞肺癌（NSCLC）的数据更新，将于本月举行的2026年世界肺癌大会（WCLC）上以口头报告形式发布。公司指引LBL-024用于一线NSCLC的III期临床试验将于2027年启动，并自上月起积极寻求全球合作伙伴。该行上调今年销售预测35.6%，并对2026至28年盈利预测作出调整（-15%、-25.7%及+14.6%），目标价由108港元上调至116.9港元，维持“跑赢大市”评级。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2026-09-02/doc-iniqmshs4541952.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["EWH","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141735010","title":"维立志博-B更新2026年8月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1141735010","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141735010?lang=zh_cn&edition=full","pubTime":"2026-09-02 16:59","pubTimestamp":1788339558,"startTime":"0","endTime":"0","summary":"南京维立志博生物科技有限公司于2026年9月2日发布截至2026年8月31日止一个月之证券变动月报表。报告显示，本月公司已发行H股数量为197,670,289股，与上月持平；未上市普通股为1,221,511股，与上月相同。截至本月底，公司法定注册股本合计为人民币198,891,800元，整体股本保持稳定。公司股权激励方面，根据股东大会决议所设立的H股奖励计划，目前仍保留最高可发行或转让的H股数量为9,944,590股，本月内未新增实际发行或转让股份。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664998198","title":"里昂：升维立志博-B(09887.HK)目标价至116.9港元 LBL-024数据即将公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2664998198","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664998198?lang=zh_cn&edition=full","pubTime":"2026-09-02 13:55","pubTimestamp":1788328537,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","HK0000500386.USD","HK0000252160.HKD","HK0000252152.HKD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164762183","title":"异动解读｜维立志博-B盘中下跌5.05%，中期业绩亏损同比扩大逾三成","url":"https://stock-news.laohu8.com/highlight/detail?id=1164762183","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164762183?lang=zh_cn&edition=full","pubTime":"2026-09-01 14:11","pubTimestamp":1788243110,"startTime":"0","endTime":"0","summary":"9月1日，维立志博-B盘中下跌5.05%，报68.65港元，成交额1.42亿港元。消息面上，公司于8月31日披露中期业绩，上半年实现收入3596.9万元，期内净亏损约2.22亿元，同比扩大33.38%；经调整净亏损1.71亿元，同比扩大约16%。收入主要来自LBL-047对外授权的一次性里程碑付款及药物材料供应款项，尚无产品销售收入。尽管公司披露8月已收到Oblenio行使LBL-051选择权的1000万美元费用，且核心产品维利信NDA已获受理，但亏损持续扩大仍对市场情绪形成压制。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"维立志博亏损扩大逾三成，股价承压下跌","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198912489","title":"维立志博-B2026年中期业绩：营收3,596.9万元，经调整净亏损1.71亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1198912489","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198912489?lang=zh_cn&edition=full","pubTime":"2026-08-31 16:38","pubTimestamp":1788165488,"startTime":"0","endTime":"0","summary":"截至2026年6月30日止六个月，维立志博-B实现收入3,596.9万元，去年同期收入为0元。经调整净亏损1.71亿元，而上年同期为1.47亿元，同比扩大约16%。报告期内主要收入来自与Dianthus Therapeutics合作的候选药物LBL-047，在中国I期临床试验里程碑达成后获得的一次性收入以及向对方提供药物材料的款项。报告期内研发投入明显增加，由上年同期的1.32亿元增长44.9%至1.91亿元。维立志博-B在报告期内主要收入来自候选药物的对外授权及相关合作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"维立志博-B2026年中期业绩：营收3,596.9万元，经调整净亏损1.71亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663806075","title":"维立志博-B(09887)公布中期业绩 净亏损约2.22亿元 同比增长33.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663806075","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663806075?lang=zh_cn&edition=full","pubTime":"2026-08-31 16:36","pubTimestamp":1788165387,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 公布2026年中期业绩，实现收入3596.9万元，研发成本约1.91亿元，同比增长44.92%;行政开支同比增加15.5%至4140万元，期内亏损约2.22亿元，同比增长33.38%。2026年8月，公司收到被授权方OblenioBio就保留LBL-051行使选择权所产生的1,000万美元选择权行使费收入。这使得协议项下已收的现金对价达约3,500万美元，预计至少该金额将于2026年下半年确认为收入。此外，股权对价也将在2026年下半年确认为收入。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489402.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252152.HKD","HK0000252160.HKD","BK1161","HK0000500386.USD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131357229","title":"异动解读｜维立志博-B盘中下跌5.03%，报70.85港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1131357229","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131357229?lang=zh_cn&edition=full","pubTime":"2026-08-26 14:57","pubTimestamp":1787727471,"startTime":"0","endTime":"0","summary":"8月26日，维立志博-B盘中下跌5.03%，报70.85港元/股，成交额1.1亿港元。维立志博-B所在的生物科技行业中，同业个股表现分化，其中康希诺生物涨23.23%，信达生物涨10.29%，康方生物涨6.75%，云顶新耀涨2.82%，百济神州涨2.69%。南京维立志博生物科技股份有限公司是一家主要从事发现、开发和商业化治疗肿瘤、自身免疫性疾病以及其他严重疾病的新疗法的中国公司，核心候选药物维利信（PD-L1/4-1BB双特异性抗体）已获NMPA新药上市申请受理。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144371798","title":"维立志博-B旗下Opamtistomig（PD-L1/4-1BB双特异性抗体）用于食管鳞状细胞癌一线治疗的II期临床研究进入扩展阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=1144371798","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144371798?lang=zh_cn&edition=full","pubTime":"2026-08-25 10:27","pubTimestamp":1787624859,"startTime":"0","endTime":"0","summary":"维立志博-B宣布，其研发的Opamtistomig——一款靶向PD-L1/4-1BB的双特异性抗体，在针对食管鳞状细胞癌一线治疗的II期临床试验中，已成功推进至扩展阶段。作为双特异性抗体，Opamtistomig旨在同时阻断PD-L1介导的免疫逃逸信号，并激活4-1BB共刺激通路，从而双重增强机体抗肿瘤免疫应答。在食管鳞状细胞癌这一侵袭性强、治疗选择相对有限的癌种中，该药的前景备受关注。维立志博-B正加速推进这一临床项目，力求早日为食管鳞癌患者带来创新疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","BK1161","HK0000252160.HKD","HK0000252152.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662673200","title":"港股异动 | 维立志博-B(09887)早盘涨超5% 维利信一线治疗ESCC的Ⅱ期临床研究进入扩展阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2662673200","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662673200?lang=zh_cn&edition=full","pubTime":"2026-08-25 10:08","pubTimestamp":1787623703,"startTime":"0","endTime":"0","summary":"在安全性导入期，维利信联合化疗一线治疗ESCC患者观察到积极疗效信号，且整体安全性和耐受性良好。扩展阶段采用随机对照设计，头对头对比维利信联合化疗与替雷利珠单抗联合化疗一线治疗ESCC的疗效与安全性，以期进一步提升现有标准治疗的临床获益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1484808.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["VXUS","HK0000252152.HKD","KCAI","BK4585","HK0000252160.HKD","BK1161","BK4588","HK0000500386.USD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127124689","title":"异动解读｜维立志博-B盘中上涨5.14%，维利信一线治疗食管鳞癌Ⅱ期研究进入扩展阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=1127124689","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127124689?lang=zh_cn&edition=full","pubTime":"2026-08-25 09:55","pubTimestamp":1787622915,"startTime":"0","endTime":"0","summary":"8月25日，维立志博-B盘中上涨5.14%，报72.6港元，成交额2836.35万港元。消息面上，公司当日公告其核心药物维利信一线治疗局部晚期或转移性食管鳞癌的Ⅱ期临床研究已完成安全性导入期，在积极疗效信号及良好安全性基础上顺利进入扩展阶段。此外，维利信一线治疗肺外神经内分泌癌、小细胞肺癌及胆道癌三项POC研究已全部完成患者入组，其中EP-NEC已推进至确证性III期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维立志博盘中上涨，食管鳞癌研究进扩展阶段","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662020178","title":"维立志博-B(09887)：维利信®(奥帕替苏米单抗，PD-L1/4-1BB双特异性抗体，LBL-024)一线治疗ESCC的Ⅱ期临床研究进入扩展阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2662020178","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662020178?lang=zh_cn&edition=full","pubTime":"2026-08-25 06:56","pubTimestamp":1787612198,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，本公司自主研发的在研药物维利信一线治疗局部晚期或转移性食管鳞癌的Ⅱ期临床研究，已完成安全性导入期并在观察到的积极疗效信号及良好的安全性和耐受性基础上，顺利进入扩展阶段。截至目前，维利信一线治疗肺外神经内分泌癌、小细胞肺癌及胆道癌的三项POC研究已全部完成患者入组，其中一线EP-NEC已进入确证性III期临床阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1484740.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4023","LU1169590202.USD","BK1161","HK0000252152.HKD","09887","PD","HK0000252160.HKD","LU1169589451.USD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193215554","title":"维立志博-B的Opamtistomig（PD-L1/4-1BB双特异性抗体）新药申请获国家药监局受理，有望成为全球首款获批的4-1BB靶向疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1193215554","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193215554?lang=zh_cn&edition=full","pubTime":"2026-08-21 17:22","pubTimestamp":1787304133,"startTime":"0","endTime":"0","summary":"维立志博-B宣布，其研发的Opamtistomig——一款靶向PD-L1与4-1BB的双特异性抗体——已向国家药品监督管理局提交的新药申请正式获得受理。这一进展标志着该公司在肿瘤免疫治疗领域迈出关键一步，也让该药物有望成为全球首个获批上市的4-1BB靶向治疗药物。此次NDA受理，意味着Opamtistomig在国内的审评审批流程正式启动。维立志博方面强调，Opamtistomig的临床开发策略聚焦于差异化设计，旨在克服既往4-1BB靶向药物在安全性上的瓶颈。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","BK1161","09887","HK0000500386.USD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190829556","title":"异动解读｜维立志博-B盘中下跌5.65%，报72.05港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1190829556","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190829556?lang=zh_cn&edition=full","pubTime":"2026-08-21 09:42","pubTimestamp":1787276520,"startTime":"0","endTime":"0","summary":"8月21日，维立志博-B盘中下跌5.65%，报72.05港元/股，成交额2679.52万港元。维立志博-B所在的生物科技行业中，个股中，云顶新耀跌8.32%，百济神州跌1.93%，康方生物跌1.92%，信达生物跌0.1%，三生制药涨4.79%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660406048","title":"港股异动 | 维立志博-B(09887.HK)午后涨超10% 维利信WCLC摘要公布 三抗全球许可获1000万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660406048","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660406048?lang=zh_cn&edition=full","pubTime":"2026-08-20 14:40","pubTimestamp":1787208034,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09887","HK0000252152.HKD","HK0000500386.USD","HK0000252160.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.leadsbiolabs.com","stockEarnings":[{"period":"1week","weight":-0.0604},{"period":"1month","weight":0.1583},{"period":"3month","weight":0.1982},{"period":"6month","weight":0.2572},{"period":"1year","weight":0.0928},{"period":"ytd","weight":0.3275}],"compareEarnings":[{"period":"1week","weight":-0.0138},{"period":"1month","weight":-0.0247},{"period":"3month","weight":0.0101},{"period":"6month","weight":-0.0211},{"period":"1year","weight":-0.0051},{"period":"ytd","weight":-0.0163}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"南京维立志博生物科技股份有限公司是一家主要从事发现、开发和商业化治疗肿瘤、自身免疫性疾病以及其他严重疾病的新疗法的中国公司。该公司的主要候选药物包括LBL-024、LBL-034、LBL-033、LBL-007等。该公司的LBL-024主要用于治疗肺外神经内分泌癌（EP-NEC）、小细胞肺癌（SCLC）、胆道癌（BTC）及非小细胞肺癌（NSCLC）、食管鳞状细胞癌（ESCC）、肝细胞癌（HCC）、胃癌（GC）及其他实体瘤。该公司还开发了专有技术平台，包括LeadsBody平台（CD3 T-cell engager平台）、X-body平台（4-1BB engager平台）以及其他几个双特异性抗体及融合蛋白平台。该公司主要在国内市场开展业务。","exchange":"SEHK","name":"维立志博-B","nameEN":"LEADS BIOLABS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供维立志博-B(09887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"维立志博-B,09887,维立志博-B股票,维立志博-B股票老虎,维立志博-B股票老虎国际,维立志博-B行情,维立志博-B股票行情,维立志博-B股价,维立志博-B股市,维立志博-B股票价格,维立志博-B股票交易,维立志博-B股票购买,维立志博-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供维立志博-B(09887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}